Cargando…
Exploring the Metabolism of (+)-[(18)F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study †
Both (+)-[(18)F]flubatine and its enantiomer (−)-[(18)F]flubatine are radioligands for the neuroimaging of α4β2 nicotinic acetylcholine receptors (nAChRs) by positron emission tomography (PET). In a clinical study in patients with early Alzheimer’s disease, (+)-[(18)F]flubatine ((+)-[(18)F]1) was ex...
Autores principales: | Ludwig, Friedrich-Alexander, Fischer, Steffen, Smits, René, Deuther-Conrad, Winnie, Hoepping, Alexander, Tiepolt, Solveig, Patt, Marianne, Sabri, Osama, Brust, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017759/ https://www.ncbi.nlm.nih.gov/pubmed/29461507 http://dx.doi.org/10.3390/molecules23020464 |
Ejemplares similares
-
Radiation dosimetry of the α(4)β(2) nicotinic receptor ligand (+)-[(18)F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results
por: Kranz, Mathias, et al.
Publicado: (2016) -
LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[(18)F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors
por: Ludwig, Friedrich-Alexander, et al.
Publicado: (2016) -
(+)-[(18)F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
por: Tiepolt, Solveig, et al.
Publicado: (2020) -
Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia
por: Sabri, Osama, et al.
Publicado: (2018) -
In vitro and in vivo Human Metabolism of (S)-[(18)F]Fluspidine – A Radioligand for Imaging σ(1) Receptors With Positron Emission Tomography (PET)
por: Ludwig, Friedrich-Alexander, et al.
Publicado: (2019)